Faculty Opinions recommendation of Comparison of predictive models for hepatitis C co-infection among HIV patients in Cambodia.

2020 ◽  
Author(s):  
Philip Rosenthal
Keyword(s):  
Hepatitis C ◽  
Predictive Models ◽  
Hiv Patients

scholarly journals Comparison of predictive models for hepatitis C co-infection among HIV patients in Cambodia

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jozefien Buyze ◽  
Anja De Weggheleire ◽  
Johan van Griensven ◽  
Lutgarde Lynen
Keyword(s):  
Hepatitis C ◽  
Predictive Models ◽  
Hiv Patients

Treatment of hepatitis C virus in HIV patients: a review

AIDS ◽  
2005 ◽  
Vol 19 (Suppl 3) ◽  
pp. S166-S173 ◽  
Author(s):  
Nickolas Kontorinis ◽  
Kaushik Agarwal ◽  
Douglas T Dieterich
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hiv Patients

Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy

AIDS ◽  
2014 ◽  
Vol 28 (10) ◽  
pp. 1473-1478 ◽  
Author(s):  
Eugenia Vispo ◽  
Pablo Barreiro ◽  
Zulema Plaza ◽  
Jose Vicente Fernández-Montero ◽  
Pablo Labarga ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiretroviral Therapy ◽  
Chronic Hepatitis C ◽  
Hiv Patients ◽  
Virus Clearance

Prevalence and histologic features of transfusion transmitted virus and hepatitis C virus coinfection in a group of HIV patients

2000 ◽  
Vol 32 (7) ◽  
pp. 617-620 ◽  
Author(s):  
R. Bruno ◽  
P. Sacchi ◽  
M. Debiaggi ◽  
S.F.A. Patruno ◽  
F. Zara ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hiv Patients ◽  
Transmitted Virus ◽  
Transfusion Transmitted Virus

scholarly journals Performance and modification of EGCRISC among hepatitis C virus high-risk groups

2020 ◽  
Vol 148 ◽  
Author(s):  
E. M. El-Ghitany ◽  
Y. M. Alkassabany ◽  
A. G. Farghaly
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
High Risk ◽  
Sex Workers ◽  
Screening Tool ◽  
Risk Groups ◽  
Hcv Infection ◽  
Human Immune Deficiency Virus ◽  
Hiv Patients ◽  
Increased Risk

Abstract We have previously shown that the Egyptian Hepatitis C Virus Risk Score (EGCRISC), an Egyptian hepatitis C virus (HCV) risk-based screening tool, to be valid and cost-effective. Certain behaviours, occupations and diseases have been shown to be associated with an increased risk of exposure to HCV infection and constitute a major population reservoir of HCV infection. This study investigated the efficacy of EGCRISC in selected high-risk groups by testing 863 participants from four groups: slaughterhouse workers, illicit drug users (IDUs), female sex workers and human immune deficiency virus (HIV) patients. Data for this study were collected on EGCRISC and another pre-designed risk factor questionnaire. Sera were tested for HCV antibodies by ELISA. EGCRISC, at lower cut-off points, showed significantly good performance (P < 0.05) in all four groups except for females <45 years, but was reliable in detecting HCV cases (sensitivity: 84.21% and negative predictive value: 94.5%). Specific scores for IDUs and HIV patients were developed that showed high accuracy (P < 0.001). A modified EGCRISC for high-risk groups (EGCRISC-HRGs) was shown to be a valid tool that is recommended for use in high-risk populations if no other specific screening tool is available or universal screening is applied. EGCRISC for IDUs (EGCRISC-IDUs) and EGCRISC for HIV patients (EGCRISC-HIV) are useful tools for preselecting potentially HCV-infected cases for further testing in settings where serological analysis is not readily available or accessible.

scholarly journals Clinical Pharmacokinetics of Nelfinavir and Its Metabolite M8 in Human Immunodeficiency Virus (HIV)-Positive and HIV-Hepatitis C Virus-Coinfected Subjects

2005 ◽  
Vol 49 (2) ◽  
pp. 643-649 ◽  
Author(s):  
Mario Regazzi ◽  
Renato Maserati ◽  
Paola Villani ◽  
Maria Cusato ◽  
Patrizia Zucchi ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hiv Positive ◽  
Therapeutic Drug ◽  
Hiv Patients ◽  
Standard Dosage ◽  
Clinical Pharmacokinetics ◽  
Immunodeficiency Virus ◽  
The Mean

ABSTRACT In order to evaluate the potential risk of nelfinavir (NFV) accumulation in human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients with liver disease, we investigated the concentrations of NFV and M8, the active metabolite of NFV, in plasma HIV-positive (HIV+) patients coinfected with HCV. A total of 119 HIV+ subjects were included in our study: 67 HIV+ patients, 32 HIV+ and HCV-positive (HCV+) patients without cirrhosis, and 20 HIV+ and HCV+ patients with cirrhosis. Most of the enrolled patients (chronically treated) were taking NFV at the standard dosage of 1,250 mg twice a day. To assay plasma NFV and M8 concentrations, patients underwent serial plasma samplings during the dosing interval at steady state. Plasma NFV and M8 concentrations were measured simultaneously by a high-performance liquid chromatography method with UV detection. The HIV+ and HCV+ patients with and without cirrhosis had significantly lower NFV oral clearances than the HIV+ and HCV-negative individuals (28 and 58% lower, respectively; P < 0.05), which translated into higher areas under the concentration-time curves for cirrhotic and noncirrhotic patients. The NFV absorption rate was significantly lower in cirrhotic patients, resulting in a longer time to the maximum concentration in serum. The mean ratios of the M8 concentration/NFV concentration were significantly lower (P < 0.05) in HIV+ and HCV+ subjects with cirrhosis (0.06 ± 0.074) than in the subjects in the other two groups. The mean ratios for M8 and NFV were not statistically different between HIV+ and HCV-negative patients (0.16 ± 0.13) and HIV+ and HCV+ patients without cirrhosis (0.24 ± 0.17), but the interpatient variability was high. Our results indicate that the pharmacokinetics of NFV and M8 are altered in HIV+ and HCV+ patients, especially those with liver cirrhosis. Therefore, there may be a role for therapeutic drug monitoring in individualizing the NFV dosage in HIV-HCV-coinfected patients.

Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C

2010 ◽  
Vol 26 (4) ◽  
pp. 419-424 ◽  
Author(s):  
Eugenia Vispo ◽  
Pablo Labarga ◽  
Josep M. Guardiola ◽  
Pablo Barreiro ◽  
Celia Miralles ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Hiv Patients
Sign in / Sign up

Export Citation Format

Share Document